ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 8

Emerging Therapies in RCC: Shaping Future Treatment Sequences

, , ,

Experts discuss the role of belzutifan and tivozanib in the treatment paradigm for advanced renal cell carcinoma (RCC), including key findings from the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in previously treated advanced RCC patients.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data
    EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes
    EP. 3: Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC
    EP. 4: RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection
    EP. 5: Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment
    EP. 6: Navigating RCC Progression: Optimizing Treatment Sequence After the First Line
    EP. 7: Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
    Now Viewing
    EP. 8: Emerging Therapies in RCC: Shaping Future Treatment Sequences
    EP. 9: RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

    Video content above is prompted by the following:

    • With belzutifan and tivozanib gaining traction in advanced RCC, how do you see these agents fitting into the treatment paradigm?
    • Please briefly highlight the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in previously treated advanced RCC patients.
    x